mnlr and u p m m m K ~v i m n n m ~d ~w m those of the mnmbufoc and the Americln Instituted Chemiol En-a s u r n m cesponsibilic for them Suhscnpwn price per year: $315.AlChE Envmnmental Diviioi Mrmhm $45 lincludd m d u a ).lnlemarionll r a m $355 for nonmemberr 5x5 A n m m k m Addiuonal c h a w for online ims for MChE Members il N m h Amrnca 526: for
Rifabutin has been substituted for rifampicin when treating tuberculosis (TB)/HIV coinfection. However, despite reports of anti-TB treatment failure and acquired rifamycin resistance, long-term clinical outcome data are lacking. Observational analyses performed in a UK TB/HIV cohort demonstrated no difference in severe adverse events, anti-TB treatment completion, relapse frequency or subsequent rifamycin resistance when rifampicin and rifabutin were compared, using different combinations of antiretroviral therapy. Our data support the wider use of rifabutin in TB/HIV coinfection.
professionals, and clinical trials of treatment in older populations are vital if we are to ensure that all patients receive the very best care, regardless of their age.Contributors PB, RS, MDP and IW lead the team responsible for audit data.RH provided the initial idea for the analysis.PB analysed the data under the supervision of RBH and LJT.PB wrote the paper with substantial input from all authors on content, style and presentation.
Background Gastro-oesophageal reflux disease (GORD) is associated with idiopathic pulmonary fibrosis (IPF) in observational studies. It is not known if this association arises because GORD causes IPF or because IPF causes GORD, or because of confounding by factors, such as smoking, associated with both GORD and IPF. We used bidirectional Mendelian randomisation (MR), where genetic variants are used as instrumental variables to address issues of confounding and reverse causation, to examine how, if at all, GORD and IPF are causally related. Methods A bidirectional two-sample MR was performed to estimate the causal effect of GORD on IPF risk and of IPF on GORD risk, using genetic data from the largest GORD (78 707 cases and 288 734 controls) and IPF (4125 cases and 20 464 controls) genome-wide association meta-analyses currently available. Results GORD increased the risk of IPF, with an OR of 1.6 (95% CI 1.04–2.49; p=0.032). There was no evidence of a causal effect of IPF on the risk of GORD, with an OR of 0.999 (95% CI 0.997–1.000; p=0.245). Conclusions We found that GORD increases the risk of IPF, but found no evidence that IPF increases the risk of GORD. GORD should be considered in future studies of IPF risk and interest in it as a potential therapeutic target should be renewed. The mechanisms underlying the effect of GORD on IPF should also be investigated.
Asthma is a common chronic childhood respiratory disease long-known to be both strongly heritable and to have important environmental determinants. In recent years genome-wide association studies (GWAS) have emerged as an indispensable tool to help understand the complex gene-environment relationships that determine asthma susceptibility and phenotype, including response to treatment.
'%3e%3cpath fill='%23012169' d='M0 0v30h60V0z'/%3e%3cpath stroke='%23fff' stroke-width='6' d='m0 0 60 30m0-30L0 30'/%3e%3cpath stroke='%23C8102E' stroke-width='4' d='m0 0 60 30m0-30L0 30' clip-path='url(%23b)'/%3e%3cpath stroke='%23fff' stroke-width='10' d='M30 0v30M0 15h60'/%3e%3cpath stroke='%23C8102E' stroke-width='6' d='M30 0v30M0 15h60'/%3e%3c/g%3e%3c/svg%3e)
